BeiGene, Ltd. (ONC)vsSol Gel Technologies Ltd (SLGL)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
SLGL
Sol Gel Technologies Ltd
$80.01
+20.86%
HEALTHCARE · Cap: $99.10M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 22227% more annual revenue ($5.34B vs $23.93M). ONC leads profitability with a 5.4% profit margin vs -14.2%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
SLGL
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 65.1%
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
2.2% revenue growth
4.9% earnings growth
Smaller company, higher risk/reward
ROE of -10.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : SLGL
The strongest argument for SLGL centers on Operating Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : SLGL
The primary concerns for SLGL are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while SLGL is a turnaround play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.38 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 40/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?